This is a free preview for the upcoming TCR2 Therapeutics Inc.
Company: TCR2 Therapeutics Inc.
Symbol: TCRR
Description: They are an innovative immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer.
Shares: 5 million
Price Range: $14.00-$16.00
Trade Date: 2/14
Underwriter(s): Jefferies, Leerink, BMO Capital
Co-Manager(s): Wedbush Capital, China Renaissance
Terms Added: 2-1-19
Business : Their proprietary TCR Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex, which we believe is essential for T cell therapies to be effective in patients with solid tumors. They have also designed our TRuC-T cells so that tumor cell recognition does not require human leukocyte antigens (HLA), which provides two important additional benefits. First, in contrast to current engineered T cell therapies that use the full TCR (TCR-T cells), their technology is designed so that it can be applied to all patients that express the cancer surface antigen irrespective of HLA subtype, which they believe will allow them to address a significantly larger patient population. Second, HLA is downregulated or lost in many tumors which can prevent their recognition by T cells and lead to diminished response rates and higher relapse rates. They therefore believe their approach will allow them to deliver the first HLA-independent TCR-T cell therapy for patients with solid tumors. They also believe that their product candidates have the potential to improve upon the efficacy and safety of currently approved chimeric antigen receptor T (CAR-T)cell therapies in CD19-positive B-cell hematological malignancies. This belief is based on preclinical studies comparing our product candidates to CAR-T cells that they engineered.
Indications of Interest: Their existing stockholders (or their affiliates), including those affiliated with certain of our directors, have indicated an interest in purchasing an aggregate of approximately $30.0 million of shares of our common stock in this offering at the initial public offering price.
IPO Boutiuqe Color, Commentary & Book-Building Status: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.
IPO Boutique subscription clients receive daily updates on this critical information.
Conclusion: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a track record with our performance for last 12 years at our website. Additionally, here’s a 2017 recap of our performance to showcase the value of IPO Boutique’s service.
Indicate with confidence, SUBSCRIBE today.
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish